Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.91 |
| ▸ | GSK3A | P49840 | 10/20 | 0.91 |
| ▸ | TERT | O14746 | 5/20 | 0.86 |
| ▸ | NPC1 | O15118 | 1/20 | 0.80 |
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
| ▸ | RAB9A | P51151 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | GAA | P10253 | 1/20 | 0.78 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.73 |
| ▸ | AURKA | O14965 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14604056 | 0.95 | GSK3B (1.00) | GSK3BGSK3ATERTNPC1USP2 | |
| SCHEMBL394120 | 0.93 | TERT (1.00) | GSK3BGSK3ATERTAURKA | |
| SCHEMBL14603994 | 0.92 | GSK3B (0.85) | GSK3BGSK3ATERTNPC1USP2 | |
| SCHEMBL14604095 | 0.88 | GSK3B (1.00) | GSK3BGSK3ATERTAURKA | |
| SCHEMBL14604015 | 0.88 | TERT (0.87) | GSK3BGSK3ATERTNPC1USP2 | |
| SCHEMBL29264950 | 0.87 | GSK3A (0.74) | GSK3BGSK3ATERTNPC1USP2 | |
| SCHEMBL29264941 | 0.87 | GSK3B (0.74) | GSK3BGSK3ATERTNPC1USP2 | |
| SCHEMBL16944431 | 0.85 | GSK3B (0.98) | GSK3BGSK3ATERTNPC1USP2 | |
| SCHEMBL16944474 | 0.85 | GSK3B (1.00) | GSK3BGSK3ANPC1USP2RAB9A | |
| SCHEMBL14603920 | 0.84 | GSK3B (0.77) | GSK3BGSK3ATERTNPC1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106042-B2 | 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives useful as modulator of nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2012-01-31 | — | — | US | disclosed |
| US-8101598-B2 | 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use | NEUROSEARCH A/S (DK) | 2012-01-24 | — | — | US | disclosed |
| US-20110105478-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS MODULATOR OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2011-05-05 | — | — | US | disclosed |
| US-20100317654-A1 | 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | ANIONA APS (DK) | 2010-12-16 | — | — | US | disclosed |
| EP-2257550-A1 | NOVEL 1,4-DIAZA-BICYCLOÝ3.2.2¨NONYL OXADIAZOLYL DERIVATIVES USEFUL AS MODULATOR OF NICOTINIC ACETYLCHOLINE RECEPTORS | NeuroSearch A/S (DK) | 2010-12-08 | — | — | EP | disclosed |
| US-7807667-B2 | 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use | NEUROSEARCH A/S (DK) | 2010-10-05 | — | — | US | disclosed |
| EP-2032575-B1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVE AND ITS MEDICAL USE | NEUROSEARCH AS (DK) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009112460-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS MODULATOR OF NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2009-09-17 | — | — | WO | disclosed |
| US-20090118266-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | CANADIAN IMPERIAL BANK OF COMMERCE AS AGENT | 2009-05-07 | — | — | US | disclosed |
| EP-2032575-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138038-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105478-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES USEFUL AS MODULATOR OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA3, CHRNA2, CHRNA4 | GSK3B 587/4885GSK3A 572/4885TERT 3979/4885 |
| US-20090118266-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | CHRNA3, CHRNA2, CHRNA5 | GSK3B 521/4885GSK3A 512/4885TERT 4050/4885 |
| US-20100317654-A1 | 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | CHRNA3, CHRNA2, CHRNA6 | GSK3B 534/4885GSK3A 517/4885TERT 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.